The national key research and development project participated by VCANBIO has been officially approved by the Ministry of Science and TechnologyZhitong·Oct 12, 2025 at 10:22 PM600645+1.52%
VCANBIO's subsidiary VUM02 injection has been approved for clinical trialsZhitong·Sep 9, 2025 at 05:21 AM600645+1.52%
VCANBIO: Net profit of 57.7705 million yuan in the first half of 2025, a year-on-year decrease of 32.18%Zhitong·Aug 27, 2025 at 04:50 AM600645+1.52%
VCANBIO plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng CompanyZhitong·Jul 29, 2025 at 06:12 AM600645+1.52%
VCANBIO has reached a strategic cooperation with Carbon Cloud IntelligenceZhitong·Jun 25, 2025 at 04:21 AM600645+1.52%
VCANBIO's subsidiary VUM02 injection clinical trial application has received an acceptance noticeZhitong·Jun 23, 2025 at 05:13 AM600645+1.52%
VCANBIO: Yang Xinzhe resigns from the position of Vice General Manager and Secretary of the BoardZhitong·Apr 9, 2025 at 02:38 AM600645+1.52%
VCANBIO's subsidiary VUM03 injection has received the drug clinical trial approval noticeZhitong·Mar 31, 2025 at 02:38 AM600645+1.52%
[Schedule Release] The 2025 Fourth Yangtze River Delta Single-Cell Genomics Technology Application Forum and Spatial Genomics Frontier Forum is grandly presented in the New Year, featuring a gathering of industry leaders, with free registration now open!生物谷·Feb 11, 2025 at 12:45 AM688114+2.20%600645+1.52%
VCANBIO's subsidiary VUM03 injection clinical trial application has received an acceptance noticeZhitong·Jan 2, 2025 at 03:59 AM600645+1.52%
VCANBIO: VUM02 injection for the treatment of active moderate to severe ulcerative colitis clinical trial approvedZhitong·Dec 17, 2024 at 03:17 AM600645+1.52%
